Tags » Hemophilia A

Alnylam and Collaborators Publish Pre-clinical Study Results in Nature Medicine on ALN-AT3

Alnylam and Collaborators Publish Pre-clinical Study Results in Nature Medicine on ALN-AT3, an Investigational RNAi Therapeutic Targeting Antithrombin (AT) for the Treatment of Hemophilia and Rare Bleeding Disorders (RBD) 2,142 more words


Lettuce Pills May Help Treat Haemophilia

Dec 16, 2014 |By Elie Dolgin

The food in Anita’s bowl is not your average dog chow. Although the dish contains pellets and wet food, there is also a sprinkling of green powder—the product of a trailblazing experiment to address a potentially lethal complication of haemophilia treatment. 1,910 more words


Roche presents data for hemophilia A therapy ACE910

  • Phase I data indicate antibody therapy ACE910 is well tolerated and has a promising efficacy profile in severe hemophilia A
  • Early data indicate encouraging reduction in bleeding rates in all patients…
  • 920 more words

NovoEight®, phase 3 data show reduction in annualised bleeding rate over time in people with haemophilia A

San Francisco, US, 7 December 2014 – Today, Novo Nordisk announced a new analysis of phase 3 data demonstrating people with haemophilia A who had the highest annualised bleeding rate (ABR) during initial treatment with NovoEight® (turoctocog alfa) showed the largest reduction in bleeding over the duration of treatment. 621 more words


Bayer Submits Biologics License Application for BAY 81-8973 for the Treatment of Hemophilia A in Adults and Children

WHIPPANY, N.J., Dec. 17, 2014 /PRNewswire/ — Bayer HealthCare has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval for BAY 81-8973, a recombinant Factor VIII (rFVIII) compound, for the treatment of hemophilia A in children and adults. 706 more words


World Hemophilia Day 2015: April 17

The World Federation of Hemophilia (WFH), an international not-for-profit organization established in 1963, provides global leadership to improve and support care for people with inherited bleeding disorders, including Hemophilia, von Willebrand Disease, rare clotting factor deficiencies, and inherited platelet disorders. 216 more words

Rare Diseases

Treatment for haemophilia A patients developing Factor VIII inhibitors

Apitope’s ATX-F8-117 granted orphan medicinal product designation for treatment of haemophilia A

Published on November 25, 2014 at 7:17 AM at NewsMedical.com

Apitope, the drug discovery and development company focused on disease-modifying treatments for patients with autoimmune and allergic diseases, announced today that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) has granted orphan medicinal product designation to ATX-F8-117 for the treatment of haemophilia A. 327 more words